The ARROW trial
A clinical trial of BLU-667 for NSCLC, MTC and other RET-altered tumors
ARROW will test an investigational drug called BLU-667 in people who have RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) or another solid tumor that has a RET fusion or mutation*. It is a phase 1 trial designed to test the safety and preliminary clinical activity of BLU-667, and to identify the best dose for future clinical trials.
BLU-667 is designed to block the activity of the mutated RET gene. In certain forms of cancer, gene or DNA alterations may occur and cause tumors to grow. RET fusions and mutations are specific genetic alterations that sometimes occur in people with NSCLC, MTC and other solid tumors. BLU-667 is an oral drug taken by mouth daily. It is an investigational drug only available through clinical trials.*RET fusions and mutations may be identified by your doctor with a tumor biopsy or a blood test.
Trial phase: Phase 1
Trial status: Active and recruiting participants
Enrollment goal: 115 people
Chance of receiving active treatment
NSCLC with a known RET fusion*
MTC (a known RET mutation is not required)*
Other solid tumor with a known RET fusion or mutation*
At least 18 years old
Unresectable disease (not eligible for surgery) for which all standard therapy options have been exhausted**
Tumor imaging by computerized tomography (CT)
Heart monitoring (ECG)
Additional assessments may be required and will be explained to you by the trial doctor.
Additional clinical sites in the United States and other countries are planned.
A travel support program is available for participants and caregivers to reduce out-of-pocket expenses and ensure travel to the trial site is simple and comfortable.
More information about this clinical trial, including participating trial sites, is available on ClinicalTrials.gov
If you think you meet the criteria specified above and are interested in taking part in the ARROW trial, or you would simply like more information, please call: 617-714-6707 or email firstname.lastname@example.org.
A member of our team will talk you through the next steps, and will connect you to a suitable trial doctor.